

## ■ Hematopoietic Cell Transplantation in Japan Annual Report of Nationwide Survey 2022 Summary Slide

The following slides contained the errors described below. We sincerely apologize for the error.

Original file

[Nationwide\_Survey\_fy2022\_sep\_vol\_20230331\_eng\_pic.pptx]

Corrected file

[Nationwide\_Survey\_fy2022\_sep\_vol\_20230411\_eng\_pic.pptx]

Slide	Slide 23	
	horizontal (X) axis labels	vertical (Y) axis labels
Incorrect / Correct	(Incorrect) 移植実施年  (Correct) Year	(Incorrect) 高リスク群 割合  (Correct) Proportion

Slide	Slide 24	
	horizontal (X) axis labels	vertical (Y) axis labels
Incorrect / Correct	(Incorrect) 移植実施年  (Correct) Year	(Incorrect) 骨髓非破壊的前治療群 割合  (Correct) Proportion

## ■ Hematopoietic Cell Transplantation in Japan Annual Report of Nationwide Survey 2020 Summary Slide

The following slides contained the errors described below. We sincerely apologize for the error.

Original file

[Nationwide\_Survey\_fy2020\_sep\_vol\_20210331\_eng\_pic.pptx]

Corrected file

[Nationwide\_Survey\_fy2020\_sep\_vol\_20220328\_eng\_pic.pptx]

Slide	Slide 41	Slide 42
	Description about the analysis population in the title bar	Description about the analysis population in the title bar
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for AML, <u>1991</u> -2019 <Allogeneic> (Age≤15)  (Correct) Survival after Allogeneic Transplants for AML, <u>2010</u> -2019 <Allogeneic> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for AML, <u>1991</u> -2019 <Allogeneic> (Age≥16)  (Correct) Survival after Allogeneic Transplants for AML, <u>2010</u> -2019 <Allogeneic> (Age≥16)

Slide	Slide 43	Slide 44	Slide 45
	Description about the analysis population in the title bar	Description about the analysis population in the title bar	Description about the analysis population in the title bar
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for AML, <u>1991</u> -2019 <HLA-identical Sibling> (Age≤15)  (Correct) Survival after Allogeneic Transplants for AML, <u>2010</u> -2019 <HLA-identical Sibling> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for AML, <u>1991</u> -2019 <HLA-identical Sibling> (Age≥16)  (Correct) Survival after Allogeneic Transplants for AML, <u>2010</u> -2019 <HLA-identical Sibling> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for AML, <u>1991</u> -2019 <UR-BM> (Age≤15)  (Correct) Survival after Allogeneic Transplants for AML, <u>2010</u> -2019 <UR-BM> (Age≤15)

Slide	Slide 46	Slide 47	Slide 48
	Description about the analysis population in the title bar	Description about the analysis population in the title bar	Description about the analysis population in the title bar
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for AML, <u>1991</u> -2019 <UR-BM> (Age≥16)  (Correct) Survival after Allogeneic Transplants for AML, <u>2010</u> -2019 <UR-BM> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for AML, <u>1991</u> -2019 <UR-CB> (Age≤15)  (Correct) Survival after Allogeneic Transplants for AML, <u>2010</u> -2019 <UR-CB> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for AML, <u>1991</u> -2019 <UR-CB> (Age≥16)  (Correct) Survival after Allogeneic Transplants for AML, <u>2010</u> -2019 <UR-CB> (Age≥16)

Slide	Slide 49	Slide 50
	Description about the analysis population in the title bar	Description about the analysis population in the title bar
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for ALL, <u>1991</u> -2019 <Allogeneic> (Age≤15)  (Correct) Survival after Allogeneic Transplants for ALL, <u>2010</u> -2019 <Allogeneic> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for ALL, <u>1991</u> -2019 <Allogeneic> (Age≥16)  (Correct) Survival after Allogeneic Transplants for ALL, <u>2010</u> -2019 <Allogeneic> (Age≥16)

Slide	Slide 51	Slide 52	Slide 53
	Description about the analysis population in the title bar	Description about the analysis population in the title bar	Description about the analysis population in the title bar
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for ALL, <u>1991</u> -2019 <HLA-identical Sibling> (Age≤15)  (Correct) Survival after Allogeneic Transplants for ALL, <u>2010</u> -2019 <HLA-identical Sibling> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for ALL, <u>1991</u> -2019 <HLA-identical Sibling> (Age≥16)  (Correct) Survival after Allogeneic Transplants for ALL, <u>2010</u> -2019 <HLA-identical Sibling> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for ALL, <u>1991</u> -2019 <UR-BM> (Age≤15)  (Correct) Survival after Allogeneic Transplants for ALL, <u>2010</u> -2019 <UR-BM> (Age≤15)

Slide	Slide 54	Slide 55	Slide 56
	Description about the analysis population in the title bar	Description about the analysis population in the title bar	Description about the analysis population in the title bar
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for ALL, <u>1991</u> -2019 <UR-BM> (Age≥16)  (Correct) Survival after Allogeneic Transplants for ALL, <u>2010</u> -2019 <UR-BM> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for ALL, <u>1991</u> -2019 <UR-CB> (Age≤15)  (Correct) Survival after Allogeneic Transplants for ALL, <u>2010</u> -2019 <UR-CB> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for ALL, <u>1991</u> -2019 <UR-CB> (Age≥16)  (Correct) Survival after Allogeneic Transplants for ALL, <u>2010</u> -2019 <UR-CB> (Age≥16)

Slide	Slide 57	Slide 58
	Description about the analysis population in the title bar	Description about the analysis population in the title bar
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for CML, <u>1991</u> -2019 <Allogeneic> (Age≤15)  (Correct) Survival after Allogeneic Transplants for CML, <u>2010</u> -2019 <Allogeneic> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for CML, <u>1991</u> -2019 <Allogeneic> (Age≥16)  (Correct) Survival after Allogeneic Transplants for CML, <u>2010</u> -2019 <Allogeneic> (Age≥16)

Slide	Slide 59	Slide 60	Slide 61
	Description about the analysis population in the title bar	Description about the analysis population in the title bar	Description about the analysis population in the title bar
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for CML, <u>1991</u> -2019 <HLA-identical Sibling> (Age≥16)  (Correct) Survival after Allogeneic Transplants for CML, <u>2010</u> -2019 <HLA-identical Sibling> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for CML, <u>1991</u> -2019 <UR-BM> (Age≥16)  (Correct) Survival after Allogeneic Transplants for CML, <u>2010</u> -2019 <UR-BM> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for CML, <u>1991</u> -2019 <UR-CB> (Age≥16)  (Correct) Survival after Allogeneic Transplants for CML, <u>2010</u> -2019 <UR-CB> (Age≥16)

Slide	Slide 62	Slide 63
	Description about the analysis population in the title bar	Description about the analysis population in the title bar
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for MDS, <u>1991</u> -2019 <Allogeneic> (Age≤15)  (Correct) Survival after Allogeneic Transplants for MDS, <u>2010</u> -2019 <Allogeneic> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for MDS, <u>1991</u> -2019 <Allogeneic> (Age≥16)  (Correct) Survival after Allogeneic Transplants for MDS, <u>2010</u> -2019 <Allogeneic> (Age≥16)

Slide	Slide 64	Slide 65	Slide 66
	Description about the analysis population in the title bar	Description about the analysis population in the title bar	Description about the analysis population in the title bar
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for MDS, <u>1991</u> -2019 <HLA-identical Sibling> (Age≤15)  (Correct) Survival after Allogeneic Transplants for MDS, <u>2010</u> -2019 <HLA-identical Sibling> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for MDS, <u>1991</u> -2019 <HLA-identical Sibling> (Age≥16)  (Correct) Survival after Allogeneic Transplants for MDS, <u>2010</u> -2019 <HLA-identical Sibling> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for MDS, <u>1991</u> -2019 <UR-BM> (Age≤15)  (Correct) Survival after Allogeneic Transplants for MDS, <u>2010</u> -2019 <UR-BM> (Age≤15)

Slide	Slide 67	Slide 68	Slide 69
	Description about the analysis population in the title bar	Description about the analysis population in the title bar	Description about the analysis population in the title bar
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for MDS, <u>1991</u> -2019 <UR-BM> (Age≥16)  (Correct) Survival after Allogeneic Transplants for MDS, <u>2010</u> -2019 <UR-BM> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for MDS, <u>1991</u> -2019 <UR-CB> (Age≤15)  (Correct) Survival after Allogeneic Transplants for MDS, <u>2010</u> -2019 <UR-CB> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for MDS, <u>1991</u> -2019 <UR-CB> (Age≥16)  (Correct) Survival after Allogeneic Transplants for MDS, <u>2010</u> -2019 <UR-CB> (Age≥16)

Slide	Slide 70	Slide 71
	Description about the analysis population in the title bar	Description about the analysis population in the title bar
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for NHL, <u>1991</u> -2019 <Allogeneic> (Age≤15)  (Correct) Survival after Allogeneic Transplants for NHL, <u>2010</u> -2019 <Allogeneic> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for NHL, <u>1991</u> -2019 <Allogeneic> (Age≥16)  (Correct) Survival after Allogeneic Transplants for NHL, <u>2010</u> -2019 <Allogeneic> (Age≥16)

Slide	Slide 72	Slide 73	Slide 74
	Description about the analysis population in the title bar	Description about the analysis population in the title bar	Description about the analysis population in the title bar
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for NHL, <u>1991</u> -2019 <HLA-identical Sibling> (Age≥16)  (Correct) Survival after Allogeneic Transplants for NHL, <u>2010</u> -2019 <HLA-identical Sibling> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for NHL, <u>1991</u> -2019 <UR-BM> (Age≤15)  (Correct) Survival after Allogeneic Transplants for NHL, <u>2010</u> -2019 <UR-BM> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for NHL, <u>1991</u> -2019 <UR-BM> (Age≥16)  (Correct) Survival after Allogeneic Transplants for NHL, <u>2010</u> -2019 <UR-BM> (Age≥16)

Slide	Slide 75	Slide 76
	Description about the analysis population in the title bar	Description about the analysis population in the title bar
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for NHL, <u>1991</u> -2019 <UR-CB> (Age≤15)  (Correct) Survival after Allogeneic Transplants for NHL, <u>2010</u> -2019 <UR-CB> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for NHL, <u>1991</u> -2019 <UR-CB> (Age≥16)  (Correct) Survival after Allogeneic Transplants for NHL, <u>2010</u> -2019 <UR-CB> (Age≥16)

Slide	Slide 77	Slide 78
	Description about the analysis population in the title bar	Description about the analysis population in the title bar
Incorrect / Correct	(Incorrect) Survival after Autologous Transplants for MM / PCD, <u>1991</u> -2019 <Autologous> (Age≥16)  (Correct) Survival after Autologous Transplants for MM / PCD, <u>2010</u> -2019 <Autologous> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for MM / PCD, <u>1991</u> -2019 <Allogeneic> (Age≥16)  (Correct) Survival after Allogeneic Transplants for MM / PCD, <u>2010</u> -2019 <Allogeneic> (Age≥16)

Slide	Slide 79	Slide 80	Slide 81
	Description about the analysis population in the title bar	Description about the analysis population in the title bar	Description about the analysis population in the title bar
Incorrect / Correct	(Incorrect) Survival after Autologous Transplants for MM / PCD, <u>1991</u> -2019 <Autologous> (Age≥16)  (Correct) Survival after Autologous Transplants for MM / PCD, <u>2010</u> -2019 <Autologous> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for MM / PCD, <u>1991</u> -2019 <Allogeneic> (Age≥16)  (Correct) Survival after Allogeneic Transplants for MM / PCD, <u>2010</u> -2019 <Allogeneic> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for MM / PCD, <u>1991</u> -2019 <UR-BM> (Age≥16)  (Correct) Survival after Allogeneic Transplants for MM / PCD, <u>2010</u> -2019 <UR-BM> (Age≥16)

Slide	Slide 82	Slide 83
	Description about the analysis population in the title bar	Description about the analysis population in the title bar
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for AA, <u>1991</u> -2019 <Allogeneic> (Age≤15)  (Correct) Survival after Allogeneic Transplants for AA, <u>2010</u> -2019 <Allogeneic> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for AA, <u>1991</u> -2019 <Allogeneic> (Age≥16)  (Correct) Survival after Allogeneic Transplants for AA, <u>2010</u> -2019 <Allogeneic> (Age≥16)

Slide	Slide 84	Slide 85
	Description about the analysis population in the title bar	Description about the analysis population in the title bar
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for AA, <u>1991</u> -2019 <Allogeneic> (Age≤15)  (Correct) Survival after Allogeneic Transplants for AA, <u>2010</u> -2019 <Allogeneic> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for AA, <u>1991</u> -2019 <Allogeneic> (Age≥16)  (Correct) Survival after Allogeneic Transplants for AA, <u>2010</u> -2019 <Allogeneic> (Age≥16)

## ■ Hematopoietic Cell Transplantation in Japan Annual Report of Nationwide Survey 2020 Summary Slide

### -Appendix to slide 34-85 : The number of patients in each group and crude survival probabilities-

The appendix contained the errors described below. We sincerely apologize for the error.

Original file

[[Appendix\\_Table\\_OS\\_2020\\_20210325.pdf](#)]

Corrected file

[[Appendix\\_Table\\_OS\\_2020\\_20220118.pdf](#)]

Slide	Slide 41	Slide 42
	Description about the analysis population	Description about the analysis population
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for AML, <u>1991</u> -2019 <Allogeneic> (Age≤15)  (Correct) Survival after Allogeneic Transplants for AML, <u>2010</u> -2019 <Allogeneic> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for AML, <u>1991</u> -2019 <Allogeneic> (Age≥16)  (Correct) Survival after Allogeneic Transplants for AML, <u>2010</u> -2019 <Allogeneic> (Age≥16)

Slide	Slide 43	Slide 44	Slide 45
	Description about the analysis population	Description about the analysis population	Description about the analysis population
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for AML, <u>1991</u> -2019 <HLA-identical Sibling> (Age≤15)  (Correct) Survival after Allogeneic Transplants for AML, <u>2010</u> -2019 <HLA-identical Sibling> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for AML, <u>1991</u> -2019 <HLA-identical Sibling> (Age≥16)  (Correct) Survival after Allogeneic Transplants for AML, <u>2010</u> -2019 <HLA-identical Sibling> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for AML, <u>1991</u> -2019 <UR-BM> (Age≤15)  (Correct) Survival after Allogeneic Transplants for AML, <u>2010</u> -2019 <UR-BM> (Age≤15)

Slide	Slide 46	Slide 47	Slide 48
	Description about the analysis population	Description about the analysis population	Description about the analysis population
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for AML, <u>1991</u> -2019 <UR-BM> (Age≥16)  (Correct) Survival after Allogeneic Transplants for AML, <u>2010</u> -2019 <UR-BM> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for AML, <u>1991</u> -2019 <UR-CB> (Age≤15)  (Correct) Survival after Allogeneic Transplants for AML, <u>2010</u> -2019 <UR-CB> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for AML, <u>1991</u> -2019 <UR-CB> (Age≥16)  (Correct) Survival after Allogeneic Transplants for AML, <u>2010</u> -2019 <UR-CB> (Age≥16)

Slide	Slide 49	Slide 50
	Description about the analysis population	Description about the analysis population
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for ALL, <u>1991</u> -2019 <Allogeneic> (Age≤15)  (Correct) Survival after Allogeneic Transplants for ALL, <u>2010</u> -2019 <Allogeneic> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for ALL, <u>1991</u> -2019 <Allogeneic> (Age≥16)  (Correct) Survival after Allogeneic Transplants for ALL, <u>2010</u> -2019 <Allogeneic> (Age≥16)

Slide	Slide 51	Slide 52	Slide 53
	Description about the analysis population	Description about the analysis population	Description about the analysis population
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for ALL, <u>1991</u> -2019 <HLA-identical Sibling> (Age≤15)  (Correct) Survival after Allogeneic Transplants for ALL, <u>2010</u> -2019 <HLA-identical Sibling> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for ALL, <u>1991</u> -2019 <HLA-identical Sibling> (Age≥16)  (Correct) Survival after Allogeneic Transplants for ALL, <u>2010</u> -2019 <HLA-identical Sibling> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for ALL, <u>1991</u> -2019 <UR-BM> (Age≤15)  (Correct) Survival after Allogeneic Transplants for ALL, <u>2010</u> -2019 <UR-BM> (Age≤15)

Slide	Slide 54	Slide 55	Slide 56
	Description about the analysis population	Description about the analysis population	Description about the analysis population
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for ALL, <u>1991</u> -2019 <UR-BM> (Age≥16)  (Correct) Survival after Allogeneic Transplants for ALL, <u>2010</u> -2019 <UR-BM> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for ALL, <u>1991</u> -2019 <UR-CB> (Age≤15)  (Correct) Survival after Allogeneic Transplants for ALL, <u>2010</u> -2019 <UR-CB> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for ALL, <u>1991</u> -2019 <UR-CB> (Age≥16)  (Correct) Survival after Allogeneic Transplants for ALL, <u>2010</u> -2019 <UR-CB> (Age≥16)

Slide	Slide 57	Slide 58
	Description about the analysis population	Description about the analysis population
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for CML, <u>1991</u> -2019 <Allogeneic> (Age≤15)  (Correct) Survival after Allogeneic Transplants for CML, <u>2010</u> -2019 <Allogeneic> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for CML, <u>1991</u> -2019 <Allogeneic> (Age≥16)  (Correct) Survival after Allogeneic Transplants for CML, <u>2010</u> -2019 <Allogeneic> (Age≥16)

Slide	Slide 59	Slide 60	Slide 61
	Description about the analysis population	Description about the analysis population	Description about the analysis population
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for CML, <u>1991</u> -2019 <HLA-identical Sibling> (Age≥16)  (Correct) Survival after Allogeneic Transplants for CML, <u>2010</u> -2019 <HLA-identical Sibling> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for CML, <u>1991</u> -2019 <UR-BM> (Age≥16)  (Correct) Survival after Allogeneic Transplants for CML, <u>2010</u> -2019 <UR-BM> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for CML, <u>1991</u> -2019 <UR-CB> (Age≥16)  (Correct) Survival after Allogeneic Transplants for CML, <u>2010</u> -2019 <UR-CB> (Age≥16)

Slide	Slide 62	Slide 63
	Description about the analysis population	Description about the analysis population
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for MDS, <u>1991</u> -2019 <Allogeneic> (Age≤15)  (Correct) Survival after Allogeneic Transplants for MDS, <u>2010</u> -2019 <Allogeneic> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for MDS, <u>1991</u> -2019 <Allogeneic> (Age≥16)  (Correct) Survival after Allogeneic Transplants for MDS, <u>2010</u> -2019 <Allogeneic> (Age≥16)

Slide	Slide 64	Slide 65	Slide 66
	Description about the analysis population	Description about the analysis population	Description about the analysis population
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for MDS, <u>1991</u> -2019 <HLA-identical Sibling> (Age≤15)  (Correct) Survival after Allogeneic Transplants for MDS, <u>2010</u> -2019 <HLA-identical Sibling> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for MDS, <u>1991</u> -2019 <HLA-identical Sibling> (Age≥16)  (Correct) Survival after Allogeneic Transplants for MDS, <u>2010</u> -2019 <HLA-identical Sibling> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for MDS, <u>1991</u> -2019 <UR-BM> (Age≤15)  (Correct) Survival after Allogeneic Transplants for MDS, <u>2010</u> -2019 <UR-BM> (Age≤15)

Slide	Slide 67	Slide 68	Slide 69
	Description about the analysis population	Description about the analysis population	Description about the analysis population
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for MDS, <u>1991</u> -2019 <UR-BM> (Age≥16)  (Correct) Survival after Allogeneic Transplants for MDS, <u>2010</u> -2019 <UR-BM> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for MDS, <u>1991</u> -2019 <UR-CB> (Age≤15)  (Correct) Survival after Allogeneic Transplants for MDS, <u>2010</u> -2019 <UR-CB> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for MDS, <u>1991</u> -2019 <UR-CB> (Age≥16)  (Correct) Survival after Allogeneic Transplants for MDS, <u>2010</u> -2019 <UR-CB> (Age≥16)

Slide	Slide 70	Slide 71
	Description about the analysis population	Description about the analysis population
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for NHL, <u>1991</u> -2019 <Allogeneic> (Age≤15)  (Correct) Survival after Allogeneic Transplants for NHL, <u>2010</u> -2019 <Allogeneic> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for NHL, <u>1991</u> -2019 <Allogeneic> (Age≥16)  (Correct) Survival after Allogeneic Transplants for NHL, <u>2010</u> -2019 <Allogeneic> (Age≥16)

Slide	Slide 72	Slide 73	Slide 74
	Description about the analysis population	Description about the analysis population	Description about the analysis population
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for NHL, <u>1991</u> -2019 <HLA-identical Sibling> (Age≥16)  (Correct) Survival after Allogeneic Transplants for NHL, <u>2010</u> -2019 <HLA-identical Sibling> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for NHL, <u>1991</u> -2019 <UR-BM> (Age≤15)  (Correct) Survival after Allogeneic Transplants for NHL, <u>2010</u> -2019 <UR-BM> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for NHL, <u>1991</u> -2019 <UR-BM> (Age≥16)  (Correct) Survival after Allogeneic Transplants for NHL, <u>2010</u> -2019 <UR-BM> (Age≥16)

Slide	Slide 75	Slide 76
	Description about the analysis population	Description about the analysis population
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for NHL, <u>1991</u> -2019 <UR-CB> (Age≤15)  (Correct) Survival after Allogeneic Transplants for NHL, <u>2010</u> -2019 <UR-CB> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for NHL, <u>1991</u> -2019 <UR-CB> (Age≥16)  (Correct) Survival after Allogeneic Transplants for NHL, <u>2010</u> -2019 <UR-CB> (Age≥16)

Slide	Slide 77	Slide 78
	Description about the analysis population	Description about the analysis population
Incorrect / Correct	(Incorrect) Survival after Autologous Transplants for MM / PCD, <u>1991</u> -2019 <Autologous> (Age≥16)  (Correct) Survival after Autologous Transplants for MM / PCD, <u>2010</u> -2019 <Autologous> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for MM / PCD, <u>1991</u> -2019 <Allogeneic> (Age≥16)  (Correct) Survival after Allogeneic Transplants for MM / PCD, <u>2010</u> -2019 <Allogeneic> (Age≥16)

Slide	Slide 79	Slide 80	Slide 81
	Description about the analysis population	Description about the analysis population	Description about the analysis population
Incorrect / Correct	(Incorrect) Survival after Autologous Transplants for MM / PCD, <u>1991</u> -2019 <Autologous> (Age≥16)  (Correct) Survival after Autologous Transplants for MM / PCD, <u>2010</u> -2019 <Autologous> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for MM / PCD, <u>1991</u> -2019 <Allogeneic> (Age≥16)  (Correct) Survival after Allogeneic Transplants for MM / PCD, <u>2010</u> -2019 <Allogeneic> (Age≥16)	(Incorrect) Survival after Allogeneic Transplants for MM / PCD, <u>1991</u> -2019 <UR-BM> (Age≥16)  (Correct) Survival after Allogeneic Transplants for MM / PCD, <u>2010</u> -2019 <UR-BM> (Age≥16)

Slide	Slide 82	Slide 83
	Description about the analysis population	Description about the analysis population
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for AA, <u>1991</u> -2019 <Allogeneic> (Age≤15)  (Correct) Survival after Allogeneic Transplants for AA, <u>2010</u> -2019 <Allogeneic> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for AA, <u>1991</u> -2019 <Allogeneic> (Age≥16)  (Correct) Survival after Allogeneic Transplants for AA, <u>2010</u> -2019 <Allogeneic> (Age≥16)

Slide	Slide 84	Slide 85
	Description about the analysis population	Description about the analysis population
Incorrect / Correct	(Incorrect) Survival after Allogeneic Transplants for AA, <u>1991</u> -2019 <Allogeneic> (Age≤15)  (Correct) Survival after Allogeneic Transplants for AA, <u>2010</u> -2019 <Allogeneic> (Age≤15)	(Incorrect) Survival after Allogeneic Transplants for AA, <u>1991</u> -2019 <Allogeneic> (Age≥16)  (Correct) Survival after Allogeneic Transplants for AA, <u>2010</u> -2019 <Allogeneic> (Age≥16)

## ■ Activities and Outcomes of Hematopoietic Cell Transplantation in Japan Summary Slide

The following slides contained the errors described below. We sincerely apologize for the error.

	Activities and Outcomes of Hematopoietic Cell Transplantation in Japan (2015)	Activities and Outcomes of Hematopoietic Cell Transplantation in Japan (2016)	Activities and Outcomes of Hematopoietic Cell Transplantation in Japan (2017)	Activities and Outcomes of Hematopoietic Cell Transplantation in Japan (2018)	Activities and Outcomes of Hematopoietic Cell Transplantation in Japan (2019)	
Slide	Slide 8, Slide 9 Indications for hematopoietic stem cell transplants	Slide 9, Slide 10 Indications for hematopoietic stem cell transplants	Slide 9, Slide 10 Indications for hematopoietic stem cell transplants	Slide 9, Slide 10 Indications for hematopoietic stem cell transplants	Slide 9, Slide 10 Indications for hematopoietic stem cell transplants	
	Description in the title bar                    	Description in the title bar	Description in the title bar			
Incorrect / Correct	(Incorrect) Indications for Hematopoietic Stam Cell Transplants in <u>1991-2014</u>  (Correct) Indications for Hematopoietic Stam Cell Transplants in <u>1974-2014</u>	(Incorrect) Indications for Hematopoietic Stam Cell Transplants in <u>1991-2015</u>  (Correct) Indications for Hematopoietic Stam Cell Transplants in <u>1974-2015</u>	(Incorrect) Indications for Hematopoietic Stam Cell Transplants in <u>1991-2016</u>  (Correct) Indications for Hematopoietic Stam Cell Transplants in <u>1974-2016</u>	(Incorrect) Indications for Hematopoietic Stam Cell Transplants in <u>1991-2017</u>  (Correct) Indications for Hematopoietic Stam Cell Transplants in <u>1974-2017</u>	(Incorrect) Indications for Hematopoietic Stam Cell Transplants in <u>1991-2018</u>  (Correct) Indications for Hematopoietic Stam Cell Transplants in <u>1974-2018</u>	